Oleamide for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Oleamide for Health & Longevity

Created on 06/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

A fat-derived signaling molecule the body makes itself, sold cheaply as a sleep and relaxation supplement. Its main predictable effect is drowsiness. Almost all evidence comes from cells and rodents; only one small human study of a very low dose exists, the safety record is sparse, and its human relevance remains unproven. (Full Review)

Protocol

Dose
Low hundreds of mg
Marketed powder or capsule dose; no validated human protocol exists
Timing
Evening
Shortly before intended sleep, given the sedative profile
Frequency
Single evening dose
Intermittent, as-needed use more defensible than continuous daily use
Time to effect
Sleep onset
Unknown in humans
In animals, acts within a single sleep session; oral human onset unestablished
Cognition
12 weeks
Duration of the one human trial showing memory improvement

Benefits

Contraindications
  • Pregnancy or breastfeeding
  • Low blood pressure
  • On serotonergic or sedative medication
  • Operating vehicles or machinery after dosing
    •
Key Interactions
  • Sedatives and hypnotics (benzodiazepines such as triazolam, diazepam; Z-drugs such as zolpidem; barbiturates)
  • Serotonergic drugs (SSRIs such as sertraline; SNRIs such as venlafaxine; triptans; MAO inhibitors)
  • Alcohol and other central nervous system depressants
  • Cannabis and cannabinoid products (THC, CBD, FAAH inhibitors)
  • Antihypertensive medications
  • Other supplements with additive effects (melatonin, valerian, magnesium, glycine, kava, GABA, L-theanine)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Sedation and next-day grogginess
    •
  • Speculative: Unknown long-term and whole-body safety; serotonergic interaction risk; cardiovascular and blood-pressure effects
    •

Monitoring

Marker Target Why
Blood pressure ~110–125 / 70–80 mmHg Screens for low blood pressure given oleamide's in vitro vessel-relaxing action
Resting heart rate 50–70 bpm Baseline for detecting serotonergic over-activation (rapid heart rate) when combined with serotonergic drugs
Comprehensive metabolic panel Within standard reference ranges General safety baseline given the complete absence of human toxicology data
Subjective sleep latency <20 min to fall asleep Tracks the intended primary effect

Cadence: Baseline check, then reassess subjective sleep and side effects after the first 1–2 weeks, with blood-pressure checks as needed for those on antihypertensives

Qualitative Assessment

  • Sleep quality and time to fall asleep (the primary intended benefit)
  • Next-day alertness versus grogginess (key side-effect signal)
  • Daytime mood and anxiety levels
  • Daytime dizziness or lightheadedness (possible blood-pressure effect)
  • Overall energy and cognitive clarity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.